Sign In
to Vote &
Create Storyboards.
 
A clinical study on a promising treatment for Type 1 diabetes developed by a Ben-Gurion University of the Negev (BGU) researcher in collaboration with the University of Colorado Health Science Center had an "exceptional outcome" after an eight-week treatment of Alpha1-Antitrypsin (AAT).According to the study published in the Journal of Clinical Endocrinology and Metabolism, the goal was to evaluate safety and effect of a novel therapy using the anti-inflammatory serum protein Alpha1-Antitrypsin ...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard